EUVIMEDEuropean Health Evidence
Uhr Sources10/10 Journal Tree
Easy Demo

European Health Evidence

The European alternative to PubMed

EUVIMED is the European alternative to PubMed: a central, multilingual research platform for medicine, nursing, life sciences and healthcare. It brings together international and European literature sources, study registries, open-access full texts, citations and retraction notices in one search. Unlike pure bibliographic databases, EUVIMED supports the entire research process – from discovery and appraisal with LIVIA and CLARA to traceable evidence synthesis. European in focus, transparent, interoperable and designed for science and healthcare.

EuropeanMultilingualInteroperableTraceable

EUVIMED BETA

EUVIMED is currently in beta

EUVIMED is under continuous development. Features, data coverage and presentation may change or be temporarily incomplete.

Results are beta

Search results, classifications, summaries and AI-assisted assessments may be incomplete, delayed or incorrect.

Check original sources

Do not use EUVIMED results without verification for diagnosis, treatment or other clinical decisions. Always consult the original source and applicable guidelines.

Errors and feedback help us improve EUVIMED: info@euvimed.com

Lokaler Crossref-Datenbestand · journal-article

A Self‐Adjuvant Photothermal Carbon Dot‐Based Nanovaccine for Multimodal Nasopharyngeal Cancer Treatment and Prophylaxis

Ruiqi Ji, Yijun Mei, Zhiqiang Wang, Mingwu Shen, Xiangyang Shi

Advanced Healthcare Materials · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

ABSTRACT Developing a “full‐cycle” strategy that integrates both treatment and prophylaxis remains a central challenge against nasopharyngeal carcinoma (NPC). Here, a biomimetic nanovaccine (CDC/Toy@CCM) is designed by coating toyocamycin (Toy)‐loaded redox‐responsive carbon dot clusters (CDCs) with homologous cancer cell membranes (CCMs). The obtained nanovaccine exhibits an average size of 70.7 nm, a high drug loading capacity (12.3%), and a superior photothermal conversion efficiency of 48.7%. The nanovaccine leverages the homologous targeting capacity of CCMs for precise tumor homing, while the disulfide‐cross‐linked CDCs enable glutathione‐triggered drug release specifically within the tumor microenvironment for controlled chemotherapy. Under near‐infrared laser irradiation, the CDCs generate robust photothermal ablation of primary tumors, and the combination of chemotherapy and photothermal therapy (PTT) effectively induces immunogenic cell death (ICD), which synergizes the self‐adjuvant of CDCs and CCM antigens to generate significant antitumor response to suppress both primary and distant tumors in a bilateral NPC mouse model. In a prophylactic setting, the nanovaccine pre‐vaccination generates effective immune protection against subsequent tumor challenge. This work provides a promising “full‐cycle” nanoplatform that synergistically integrates PTT, chemotherapy, and immunotherapy for both NPC treatment and prophylaxis.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Ruiqi Ji, Yijun Mei, Zhiqiang Wang, Mingwu Shen, Xiangyang Shi
Quelle
Advanced Healthcare Materials
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
2192-2640, 2192-2659
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Ruiqi Ji, Yijun Mei, Zhiqiang Wang, Mingwu Shen, Xiangyang Shi (2026). A Self‐Adjuvant Photothermal Carbon Dot‐Based Nanovaccine for Multimodal Nasopharyngeal Cancer Treatment and Prophylaxis. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71703
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1 · Lizenz 2